We also proposed for the first time that OMT regulates the pathological progression of HemSCs and increases PPNL sensitivity via targeting miR-27a-3p/PPAR-γ signaling pathway through m6A modification, providing a new strategy for the treatment of patients with IH. Here, PPARG is linked to isolated hemihyperplasia.